Patents Examined by Agnes Rooke
-
Patent number: 7348416Abstract: The present invention provides a method for enriching cell surface proteins by oxidizing glycosylated protein with periodate. The present invention further provides that the cell surface proteins are obtained from intact cells either from cell lines or from tissues. The present invention provides a method not only capable of obtaining increased quantities of the cell surface proteins, but also capable of obtaining a wide ranges of proteins that are not detectable by other means.Type: GrantFiled: November 19, 2004Date of Patent: March 25, 2008Assignee: Applera CorporationInventors: Bruno Domon, Ian McCaffery, Terence Ryan
-
Patent number: 7268214Abstract: The present invention relates to a novel membrane translocating full-length peptide sequence, fragment, motif, derivative, analog or peptidomimetic thereof (MTLPs), to nucleotide sequences coding therefor, and to compositions comprising a MTLP-active agent complex and a MTLP-active particle complex. The MTLP or the nucleotide sequence coding therefor enhance movement of the active agent or of the active particle across a lipid membrane. More particularly, the present invention relates to a MTLP-active agent complex and a MTLP-active particle complex, wherein the MTLP enhances uptake of the active agent into a cell, into or out of an intracellular compartment and across a cell layer. Methods of making and methods of using MTLPs also are included.Type: GrantFiled: January 23, 2004Date of Patent: September 11, 2007Assignee: Merrion Research I LimitedInventors: Daniel J. O'Mahony, Imelda J. Lambkin
-
Patent number: 7189540Abstract: The present invention discloses highly efficient novel recognition sites for Pro39 protease. The invention further provides a wide range of conditions for protein purification and modification with the novel recognition sites. The invention even further provides expression vectors for expression of fusion proteins in cells and method to purify fusion proteins.Type: GrantFiled: June 21, 2005Date of Patent: March 13, 2007Assignee: Quattromed ASInventors: Aleksei Lulla, Kairit Tints, Signe Tobi
-
Patent number: 7169896Abstract: The present invention relates to a process for solubilizing keratins from a keratin containing starting material such as poultry feathers. The keratins are may be solubilized using a sulphide under alkaline conditions. In the process the cysteine residues of solubilized keratins and are partially modified, e.g. by alkylation. The conditions of solubilisation and partial modification are chosen such that the keratins are also partially hydrolyzed. The partially modified and partially hydrolyzed keratin may be used as stable dispersions e.g. for the production of films and coatings by casting.Type: GrantFiled: July 12, 2002Date of Patent: January 30, 2007Assignee: Stichting Nederlands Instituut voor ZuivelonderzoekInventors: Peter Marcel Myriam Schrooyen, Radulf Oberthur
-
Patent number: 7164002Abstract: This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa ), its zymogen Factor VII (FVII). The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.Type: GrantFiled: January 30, 2003Date of Patent: January 16, 2007Assignee: Genentech, Inc.Inventors: Robert A. Lazarus, Henry R. Maun
-
Patent number: 7148020Abstract: The invention provides methods and materials related to treating and diagnosing autoimmune conditions. Specifically, the invention provides polypeptide compositions, nucleic acids, substantially pure polypeptides, host cells, and methods for identifying a mammal with an autoimmune condition, treating a mammal with an autoimmune condition, and enhancing tolerance in a mammal with an autoimmune condition.Type: GrantFiled: July 11, 2002Date of Patent: December 12, 2006Assignee: Arexis ABInventors: Rikard Holmdahl, Jan Ake Engstrom, Jan Kihlberg, Harald Burkhardt
-
Patent number: 7138253Abstract: The invention provides peptides with high affinity for streptavidin. These peptides may be expressed as part of fusion proteins to facilitate the detection, quantitation, and purification of proteins of interest.Type: GrantFiled: October 28, 2004Date of Patent: November 21, 2006Assignee: The General Hospital CorporationInventors: Jack W. Szostak, David S. Wilson, Anthony D. Keefe
-
Patent number: 7122350Abstract: The present invention provides two novel E. coli synthetic promoters, Syn 1 and Syn 2. Syn 1 and Syn 2 are two tight regulated synthetic promoters that control uninduced, leaky expression of proteins that are toxic and interfere with production of recombinant protein from an E. coli expression system.Type: GrantFiled: February 9, 2005Date of Patent: October 17, 2006Assignee: ZymoGenetics, Inc.Inventors: Chung Chan, Tracey A. Pownder
-
Patent number: 7115567Abstract: The present invention describes methods of producing milligram quantities of three forms of purified Stat1 protein from recombinant DNA constructs. In addition, the Stat proteins may be isolated in their phosphorylated or nonphosphorylated forms (Tyr 701). The proteins can be produced in baculovirus infected insect cells, or E. coli. A compact domain in the amino terminus of Stat1? was isolated and found to enhance DNA binding due to its ability to interact with a neighboring Stat protein. A relatively protease-resistant recombinant truncated form of the Stat protein was isolated in 40–50 mg quantities. Purification of the Stat proteins were performed after modifying specific cysteine residues of the Stat proteins to prevent aggregation. Activated EGF-receptor partially purified from membranes by immunoprecipitation was shown to be capable of in vitro catalysis of the phosphorylation of the tyrosine residue of Stat1 known to be phosphorylated in vivo.Type: GrantFiled: September 17, 2002Date of Patent: October 3, 2006Assignee: The Rockefeller UniversityInventors: Uwe Vinkemeier, James E. Darnell, Jr.
-
Patent number: 7109000Abstract: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.Type: GrantFiled: March 1, 2002Date of Patent: September 19, 2006Assignee: CuraGen CorporationInventors: Shlomit R. Edinger, John R. MacDougall, Isabelle Millet, Karen Ellerman, David J. Stone, Valerie Gerlach, William M. Grosse, John P. Alsobrook, II, Denise M. Lepley, Daniel K. Rieger, Catherine E. Burgess, Stacie J. Casman, Kimberly A. Spytek, Ferenc L. Boldog, Li Li, Muralidhara Padigaru, Vishnu Mishra, Meera Patturajan, Suresh G. Shenoy, Luca Rastelli, Velizar T. Tchernev, Corine A. M. Vernet, Bryan D. Zerhusen, Uriel M. Malyankar, Xiaojia Guo, Charles E. Miller, Esha A. Gangolli
-
Patent number: 7094547Abstract: The present invention relates to sperm specific surface proteins, nucleic acid sequences encoding those proteins and antibodies raised against those proteins. Compositions comprising the sperm specific proteins or inhibitors of said proteins can be used in contraceptive applications.Type: GrantFiled: March 25, 2004Date of Patent: August 22, 2006Assignee: University of Virginia Patent FoundationInventors: Zhonglin Hao, John C. Herr, Friederike L. Jayes, Jagathpala Shetty, Michael J. Wolkowicz
-
Patent number: 7094756Abstract: The present invention relates to the use of the A20-binding inhibitor of NF-?B activation (ABIN), or a functional fragment or variant thereof to protect against TNF-induced liver failure, such as viral hepatitis and alcoholic liver disease. More particularly, it relates to the prevention of the toxic effects of said diseases, including lethality, by overexpressing ABIN.Type: GrantFiled: December 19, 2003Date of Patent: August 22, 2006Assignee: Vlaams Interuniversitair Instituut Voor Biotechnologie VZWInventors: Rudi Beyaert, Ben Wielockx, Sofie Van Huffel, Filip Delaei, Claude Libert
-
Patent number: 7094758Abstract: The invention provides methods and compositions for enhancing apoptosis of pathogenic cells. The general method comprises the of contacting the cells with an effective amount of an AV peptoid, wherein the AV peptoid is a peptide comprising AX1, wherein X1 is V, I or L, or a peptide mimetic thereof, which interacts with an Inhibitor of Apoptosis protein (IAP) as measured by IAP binding, procaspase-3 activation or promotion of apoptosis, wherein apoptosis of the pathogenic cells is enhanced. The subject compositions encompass pharmaceutical compositions comprising a therapeutically effective amount of a subject AV peptoid in dosage form and a pharmaceutically acceptable carrier, wherein the AV peptoid is a peptide comprising AX1, wherein X1 is V, I or L, or a peptide mimetic thereof, which inhibits the activity of an Inhibitor of Apoptosis protein (IAP) as measured by IAP binding, procaspase-3 activation or promotion of apoptosis.Type: GrantFiled: December 5, 2005Date of Patent: August 22, 2006Assignee: Board of Regents, The University of Texas SystemInventors: Xiaodong Wang, Chunying Du
-
Patent number: 7091316Abstract: The present invention relates to a novel protein (MAY-I) which exhibits immunosuppressive activity in allogeneic mixed lymphocyte reaction, and provides a gene encoding that protein, a vector containing said gene, a transformant produced by said vector, a method of manufacturing the said protein with immune activity by culturing said transformant, and a medicinal composition and the like containing the said protein.Type: GrantFiled: August 1, 2001Date of Patent: August 15, 2006Assignee: Maruho Co., Ltd.Inventors: Hiroo Uchida, Hirokazu Tanaka, Yasuhiko Kitoh, Akio Fujimura, Eiji Kobayashi
-
Patent number: 7067633Abstract: Methods of modulating macropinocytosis in cells of a target cell population by modulating the binding of Pak1 to DLC1/PIN are disclosed. In addition, the invention provides for methods of screening for modulators of macropinocytosis that involve determining whether a candidate substance inhibits or promotes the binding of Pak1 to DLC1/PIN. Also disclosed are methods of reducing cell proliferation in a target cell population, methods of inhibiting growth and survival of a cancer cell, methods of inhibiting the invasiveness of a cancer cell, and methods of treating viral infection using an agent that modifies the binding of Pak1 to DLC1/PIN.Type: GrantFiled: February 26, 2004Date of Patent: June 27, 2006Assignee: Board of Regents, The University of Texas SystemInventors: Rakesh Kumar, Ratna Vadlamudi
-
Patent number: 7064183Abstract: The methods and compositions of the present invention find use in impacting microbial pathogens and in enhancing disease resistance to pathogens, particularly by plants. The compositions of the invention include polypeptides that possess antimicrobial properties, particularly fungicidal properties, and the encoding nucleic acid molecules. The polypeptides of the invention are isolated from the hemolymph and fat bodies of insect larvae induced by injection of plant pathogenic fungi. Further provided are plant cells, plants, and seed thereof, transformed with the nucleic acid molecules of the invention so as to confer disease resistance on the plant.Type: GrantFiled: March 29, 2005Date of Patent: June 20, 2006Assignees: Pioneer Hi-Bred International, Inc., E. I. du Pont de Nemours and CompanyInventors: Daniel J. Altier, Rafael Herrmann, Albert L. Lu, Billy F. McCutchen, James K. Presnail, Janine L. Weaver, James F. H. Wong
-
Patent number: 7052870Abstract: The invention describes isolated mTOR-associated proteins (“mTOR-APs”) as well as isolated variants and fragments thereof and the isolated nucleic acids encoding them. The invention also describes vectors and host cells containing nucleic acid encoding an mTOR-AP polypeptide and methods for producing an mTOR-AP polypeptide. Also described are methods for screening for compounds which modulate mTOR-AP activity and methods for treating or preventing a disorder that is responsive to mTOR-AP modulation.Type: GrantFiled: February 18, 2004Date of Patent: May 30, 2006Assignee: Whitehead Institute for Biomedical ResearchInventors: David M. Sabatini, Do-Hyung Kim, Dos D. Sarbassov
-
Patent number: 7053050Abstract: An agent for prophylaxis or treatment of proliferative organ diseases, chronic arthritic diseases, hypertrophic scars or keloid, comprising an erythropoietin receptor antagonist or a salt thereof.Type: GrantFiled: November 1, 2002Date of Patent: May 30, 2006Assignee: Yoshiko YasudaInventors: Yoshiko Yasuda, Yukio Nakamura, Yoshihiko Fujita
-
Patent number: 7053051Abstract: Methods for making crosslinked material, such as collagen-based material, and bioprosthetic devices. The crosslinked material includes hydroxyl groups, carboxyl groups, and amine groups prior to crosslinking. The methods include removing at least a portion of the zero-length ester crosslinks in a crosslinked material and/or blocking at least a portion of the amine groups that are reactive with carboxyl groups and form zero-length crosslinks.Type: GrantFiled: October 27, 2004Date of Patent: May 30, 2006Assignee: Medtronic, Inc.Inventors: Marc Hendriks, Frank Everaerts, Mirian Gillissen, Michel Verhoeven, Mark W. Torrianni
-
Patent number: 7045607Abstract: A corn product removal process for removing zein and/or oil from dry-milled corn. Oils and/or zein are extracted from corn using ethanol. Corn solids are separated from the ethanol, oil and zein mixture produced by extracting. Thereafter, the ethanol, oil and zein mixture is membrane filtered to restrain zein from the mixture and pass an oil and ethanol mixture. The zein and/or oil may be concentrated and purified.Type: GrantFiled: August 6, 2004Date of Patent: May 16, 2006Assignee: The Board of Trustees of the University of IllinoisInventor: Munir Cheryan